Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Global X Uranium ETF — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Global X Uranium ETF trades at $34.76 (market cap $5.50B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Global X Uranium ETF for 64 Days on average.
| HNGE | URA | |
|---|---|---|
Market Cap | $8.48B | $5.50B |
Volume | 879,799 | 3,413,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $105.14 | $61.81 |
52-Week Low | $31.17 | $35.54 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $8.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
URA (Global X Uranium ETF) trades at $37.38, down 0.9% with a bearish technical signal from moving averages. The ETF provides diversified exposure to uranium miners and nuclear energy companies amid growing global nuclear adoption. Recent news highlights nuclear energy's role in meeting AI power demand and government support for reactor development. Key holdings include Cameco (over 20%) and Sprott Physical Uranium Trust (nearly 6%).
Outlook remains mixed with strong long-term nuclear demand drivers offset by recent sector volatility. Investment opportunity lies in nuclear's capacity factor advantages and policy support, while risks include uranium price fluctuations and concentrated holdings. The ETF's 18.9% correction presents potential entry point for thematic investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
